Published in Gene Therapy Weekly, January 11th, 2001
The Phase I study will evaluate the safety and efficacy of a gene therapy based on an engineered form of the gene known as hypoxia inducible factor 1 alpha (HIF-1), which has been shown in laboratory studies to turn on the expression of many proteins associated with the natural process of blood vessel formation called angiogenesis.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.